Pedro Huertas, MD, PhD

Pedro Huertas, MD, PhD has extensive experience in the pharmaceutical industry, holding various leadership roles. Pedro is currently serving as the Chief Medical Officer at AceLink Therapeutics since April 2023. Prior to that, they held the same role at Kriya Therapeutics, Inc. from August 2022 to March 2023. Pedro also worked as a Consultant at AVROBIO from June 2021 to October 2022 and at akta Pharmaceutical Development from October 2021 to August 2022. From April 2019 to August 2022, they served as a Senior Adviser at Eloxx Pharmaceuticals. Pedro has also held the position of Chief Medical Officer at Inozyme Pharma from October 2019 to January 2021 and at Sentien Biotechnologies, Inc. from September 2018 to August 2019. Previously, they worked as the Chief Medical Officer at Eloxx Pharmaceuticals from April 2015 to September 2018. Pedro began their career as a Global Medical Lead at Pfizer from January 2012 to May 2015 and continued in the same role at Shire from an unspecified time in 2008 to November 2011.

Pedro Huertas, MD, PhD has an extensive education history. Pedro began by pursuing a Bachelor's degree, but the information for this is not available. In 1983, they attended Stanford University where they obtained a Master's degree in Biochemistry, which they completed in 1985. During the same period, they also enrolled at Harvard Medical School and obtained an MD in an unspecified field of study, which they completed in 1993. Simultaneously, they pursued a PhD at Harvard University in Cell & Developmental Biology, completing it in the same year. Later, in 1997-1998, they attended the MIT Sloan School of Management, where they obtained a Master's degree in Management. It is important to note that no information is provided about Pedro Huertas' education prior to 1983 or after 1998.